Distributable cash remains constrained by elevated capital expenditures, which consistently exceeded $60 million per quarter, contributing to dividend payout ratios as high as 205% in 2024Q4.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 462.18M | 457.1M | 501.62M | 499.82M | 272.75M | 232.63M | 470.09M | 213.14M | 208.35M | 179.77M | 151.27M | 160.38M | 125.37M | 120.8M | 116.4M | 105.03M | 80.83M | 103.21M | 106.61M | 90.92M | 109.09M | 101.67M | 126.24M | 97.03M | 109.03M | 91.34M | 121.04M | 91.8M | 23.5M | 40.4M | 29.6M |
| Operating CF Growth % | -1.05% | -8.88% | 0.36% | 83.25% | 17.25% | -50.51% | 120.56% | 2.3% | 15.9% | 18.84% | -5.68% | 27.92% | 3.79% | 3.78% | 10.82% | 29.93% | -21.68% | -3.19% | 17.26% | -16.65% | 7.3% | -19.47% | 30.1% | -11% | 19.36% | -24.53% | 31.85% | 290.64% | -41.83% | 36.49% | 10.86% |
| Operating CF / Revenue % | 40.22% | 38.72% | 39.55% | 37.2% | 29.24% | 43.5% | 63.95% | 30.73% | 29.97% | 29.32% | 32.85% | 39.76% | 33.79% | 38% | 38.85% | 38.27% | 40.44% | 79.71% | 132.57% | 515.83% | - | 64.04% | 71.34% | 64.93% | 79.78% | 62.97% | 79.8% | 59.84% | 29.38% | 77.99% | 94.57% |
| Net Income | -201.25M | -246.07M | -663.9M | -282.08M | 40.69M | 66.66M | 72.19M | 39.19M | 69.77M | 23.09M | 85.57M | 69.44M | 32.2M | 6.98M | 5.54M | -184K | 8.25M | 51.15M | 41.69M | 60.06M | 39.72M | 52.67M | 55.53M | 70.51M | 70.09M | 79.89M | 79.8M | 86M | 40.5M | 31.2M | 19.7M |
| Depreciation & Amortization | 578.11M | 567.32M | 722.32M | 775.89M | 477.78M | 206.51M | 194.82M | 180.87M | 167.2M | 146.35M | 131.04M | 120.36M | 116.05M | 105.32M | 101.44M | 92.39M | 77.89M | 70.92M | 54.75M | 53.92M | 65.53M | 67.21M | 60.97M | 46.16M | 46.56M | 45.13M | 42.83M | 41.2M | 17.1M | 12.1M | 9M |
| Stock-Based Compensation | 24.79M | 22.39M | 31.82M | 14.29M | 20.35M | 10.73M | 9.92M | 12.28M | 10.69M | 10.03M | 7.6M | 6.03M | 4.45M | 5.21M | 3.49M | 2.92M | 2.41M | 3.71M | 2.78M | 96K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 50.67M | 145.75M | 437.25M | 62.62M | -233.26M | -42.74M | 242.21M | -1.46M | -2.76M | -4.58M | -7.13M | -3.57M | -10.33M | -8.18M | -73K | -4.3M | -5.5M | -26.08M | 7.24M | 12.19M | 7.97M | -5.37M | 188K | -1.54M | 2.14M | -6.81M | 668K | -4.4M | 2.7M | 600K | 400K |
| Working Capital Changes | 12.89M | -32.29M | -25.86M | -70.89M | -32.81M | -8.53M | -851K | 1.35M | 4.88M | -6.13M | -24.86M | 2.56M | -19.78M | -2.3M | 1.97M | 12.56M | -1.45M | 4.18M | -1.31M | 5.15M | -4.13M | -12.84M | 9.54M | -18.11M | -9.77M | -26.86M | -2.26M | -31M | -36.8M | -3.5M | 500K |
| Cash from Investing | 704.35M | 710.83M | 900.92M | 349.14M | 1.63B | -562.47M | -555.17M | -418.53M | -105.03M | -259.45M | -237.82M | -65.78M | -105.59M | -207.95M | -113.25M | -294.67M | -350.43M | -97.76M | -368.88M | 233.35M | -53.55M | -35.87M | -300.11M | -71.82M | 56.17M | 19.74M | -4.05M | -17.9M | -89M | -67.5M | -63.5M |
| Acquisitions (Net) | -694K | 0 | 0 | -3.82M | 1.06B | -89.6M | -65.66M | 1.23M | 0 | -8.7M | -4.57M | 0 | 0 | 0 | 0 | 0 | 0 | -184K | 882K | 0 | 126.35M | 0 | -355.47M | -83.96M | -43.74M | -53.97M | -97.75M | 0 | 0 | 0 | 0 |
| Purchase of Investments | 0 | 0 | 0 | 0 | 0 | -186.43M | -268.36M | -581.36M | -51.66M | -2.48B | -591.95M | -279.58M | 0 | 0 | 0 | -101.93M | -25.11M | -23.39M | -42.52M | 0 | -10.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sale of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 23.85M | 5.62M | 305.84M | 93.02M | 27.48M | 34.63M | 0 | 2.72M | 0 | 0 | 0 | 148.92M | 8.24M | 311.93M | 32.71M | 0 | 0 | 0 | 0 | 0 | 15.05M | 0 | 0 | 0 | 0 |
| Other Investing | 966.07M | 710.83M | 1.15B | 583.99M | 738.04M | -185.75M | -151.02M | 220.65M | -34.22M | -170.13M | -166.39M | -17.01M | -34.92M | -137.88M | -90.34M | 37.37M | 43.71M | -52.59M | 48.23M | 52.23M | -75.6M | 51.53M | 55.36M | 12.15M | 99.91M | 73.71M | 78.66M | -9.1M | -89M | -67.5M | -63.5M |
| Cash from Financing | -1.17B | -1.21B | -1.36B | -884.22M | -1.86B | 327.72M | 99.72M | 197.67M | -101.16M | 31.39M | 136.96M | -94.01M | -24.93M | 89.04M | -1.1M | 81.05M | 377.06M | -3.74M | 257.88M | -317.71M | -60.63M | -61.44M | 171.64M | -21.77M | -167.73M | -109.94M | -118.6M | -83.2M | 74.6M | 31.1M | 26.1M |
| Dividends Paid | -362.01M | -386.92M | -457.85M | -472.24M | -1.41B | -175.46M | -275.82M | -256.12M | -150.27M | -142.33M | -131.76M | -120.27M | -116.37M | -111.57M | -96.36M | -89.27M | -75.82M | -91.39M | -81.3M | -101.14M | -126.2M | -125.34M | -115.7M | -104.29M | -105.89M | -100.66M | -96.23M | -92.3M | -42.9M | -35.8M | -25.2M |
| Common Dividends | -278.11M | -386.92M | -457.85M | -472.24M | -1.41B | -175.46M | -162.56M | -155.36M | -150.27M | -142.33M | -131.76M | -120.27M | -116.37M | -111.57M | -96.36M | -89.27M | -75.82M | -91.39M | -81.3M | -101.14M | -126.2M | -125.34M | -115.7M | -104.29M | -105.89M | -100.66M | -96.23M | -92.3M | -42.9M | -35.8M | -25.2M |
| Debt Issuance (Net) | -3M | -1000K | -1000K | -1000K | -1000K | 1000K | 1000K | 1000K | 1000K | -1000K | -1000K | -1000K | 1000K | -1000K | -1000K | -1000K | -1000K | 1000K | 1000K | -1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | -1000K | 1000K | 1000K | -1000K | 1000K |
| Share Repurchases | -103.79M | -4.01M | -519.3M | -2.3M | -3.19M | -3.8M | -1.44M | -5.1M | -4.53M | -1.69M | -1.76M | -1.37M | -10.07M | -454K | -68K | -86K | -51.86M | -8K | -282K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 54.87M | -23.17M | -6.78M | -5.65M | -14.45M | -405K | 245.06M | -38.86M | -6.95M | 244.55M | -4.62M | 231.46M | 66.87M | 216.94M | 387.73M | 4.8M | 378.97M | 563.42M | -156K | -227.36M | -11.46M | 0 | -2.57M | 15.98M | 0 | 0 | 113K | -200K | -100K | 0 | -200K |
| Net Change in Cash | 361K | -42.74M | 43.22M | -35.26M | 47.79M | -2.13M | 14.65M | -7.72M | 2.17M | -48.29M | 50.41M | 583K | -5.15M | 1.9M | 2.04M | -108.58M | 107.47M | 1.71M | -4.38M | 6.57M | -5.09M | 4.35M | -2.23M | 3.44M | -2.53M | 1.14M | -1.61M | -9.3M | 74.6M | 31.1M | 26.1M |
| Exchange Rate Effect | -152K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.8M | 141.81M | -52.24M | 2.07M | -2.52M | 230K | -55.57M | 148.8M | -297.2M | 88.96M | 127.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 65.5M | 27.1M | 33.9M |
| Cash at Beginning | 26.17M | 68.92M | 25.7M | 60.96M | 13.18M | 15.3M | 657K | 8.38M | 6.21M | 54.51M | 4.1M | 3.52M | 8.67M | 6.78M | 4.74M | 113.32M | 5.85M | 4.14M | 8.52M | 1.95M | 7.04M | 2.68M | 4.92M | 402K | 2.93M | 1.79M | 3.4M | 12.7M | 5.3M | 1.4M | 9.1M |
| Cash at End | 26.23M | 26.17M | 68.92M | 25.7M | 60.96M | 13.18M | 15.3M | 657K | 8.38M | 6.21M | 54.51M | 4.1M | 3.52M | 8.67M | 6.78M | 4.74M | 113.32M | 5.85M | 4.14M | 8.52M | 1.95M | 7.04M | 2.68M | 3.84M | 402K | 2.93M | 1.79M | 3.4M | 79.9M | 32.5M | 35.2M |
| Free Cash Flow | 201.16M | 126.94M | 252.64M | 268.79M | 109.2M | 131.94M | 376.13M | 148.47M | 137.55M | 99.15M | 79.84M | 111.61M | 54.7M | 48.01M | 93.49M | -125.07M | -288.2M | -67.31M | -277.09M | -39.88M | -17.26M | 14.27M | 126.24M | 97.03M | 109.03M | 91.34M | 121.04M | 83M | 23.5M | 40.4M | 29.6M |
| FCF Growth % | -2.13% | -49.75% | -6.01% | 146.14% | -17.23% | -64.92% | 153.34% | 7.94% | 38.72% | 24.19% | -28.46% | 104.03% | 13.93% | -48.64% | 174.75% | 56.6% | -328.19% | 75.71% | -594.83% | -131.06% | -220.98% | -88.7% | 30.1% | -11% | 19.36% | -24.53% | 45.83% | 253.19% | -41.83% | 36.49% | 10.86% |
| FCF / Revenue % | 17.51% | 10.75% | 19.92% | 20% | 11.71% | 24.67% | 51.17% | 21.4% | 19.78% | 16.17% | 17.34% | 27.67% | 14.74% | 15.1% | 31.2% | -45.57% | -144.19% | -51.98% | -344.56% | -226.25% | - | 8.99% | 71.34% | 64.93% | 79.78% | 62.97% | 79.8% | 54.11% | 29.38% | 77.99% | 94.57% |
Dividend coverage and capital intensity
As reported in recent financial statements, Healthcare Realty Trust has struggled to maintain dividend coverage, with AFFO failing to cover distributions in multiple quarters, including a 106% payout ratio in 2025Q3 and a 205% ratio in 2024Q4, indicating significant pressure on the company's cash-based distribution capacity.
The recurring inability to cover dividends with AFFO suggests that the current payout level may be unsustainable without reliance on external financing or asset sales. Investors should monitor whether management prioritizes dividend preservation over the capital expenditures required to maintain the competitiveness of their on-campus medical office portfolio.
Based on the provided cash flow data, property-level capital expenditures remain elevated, consistently exceeding $60 million per quarter, which directly suppresses the REIT's AFFO and limits the cash available for distribution to shareholders after accounting for necessary tenant improvements and building maintenance requirements.
The high level of capital intensity appears to be a structural feature of the portfolio, likely driven by the need to modernize aging on-campus facilities to retain high-value physician tenants. This ongoing requirement for capital reinvestment suggests that the company's true free cash flow is significantly lower than headline FFO figures might imply.
Financial filings reveal a persistent disconnect between GAAP net income and FFO, with the company reporting negative net income in nine of the last ten quarters, while FFO remained positive in most periods, highlighting the distortive impact of non-cash depreciation and potential impairment charges on reported earnings.
The consistent gap between GAAP losses and positive FFO suggests that investors should focus exclusively on cash-based metrics to evaluate performance. However, the volatility in FFO itself warrants caution, as it may not fully capture the cash-draining effects of the heavy capital expenditure requirements identified in the portfolio.
According to the company's reported figures, the conversion of GAAP operating cash flow into FFO has been erratic, with FFO/NI ratios showing extreme swings, such as the -944.23 ratio in 2026Q1, which underscores the difficulty in reconciling accounting earnings with actual cash-generating capacity post-merger.
This lack of stability in conversion metrics suggests that the company's cash flow profile is currently unpredictable, likely due to integration-related accounting adjustments and fluctuating operational costs. Analysts should remain skeptical of short-term improvements in FFO until the company demonstrates a more consistent relationship between its operating cash flow and core earnings.
Quick answers to the most common questions about buying HR stock.
Healthcare Realty Trust Incorporated (HR) generated $457.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Healthcare Realty Trust Incorporated (HR) generated $126.9M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Healthcare Realty Trust Incorporated (HR) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Healthcare Realty Trust Incorporated (HR) returned $386.9M to shareholders via cash dividends and spent $4.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.